Pfizer's Art Of The Deal
1. Pfizer and Trump agreed to cut drug prices for Medicaid patients. 2. Pfizer avoids 100% tariffs for three years, boosting share prices by 16%. 3. Deal impacts only a fraction of Pfizer's revenue and has limited bottom-line effect. 4. Agreement focuses on optics over substantive financial changes for Pfizer. 5. Other pharma companies may replicate Pfizer's strategy for regulatory stability.